Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01681186 · ClinicalTrials.gov registry record · Phase 1
A Study of LY2940680 in Healthy Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT01681186 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 30 participants.
The verdict
NCT01681186, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
This study involves 2 parts, Part A and Part B. The purpose of Part A is to evaluate the safety and side effects of LY2940680 in healthy participants. Part A will involve two groups of participants, each taking up to two single doses of LY2940680 at different dose levels. There is a minimum 14 day washout period between each of the participant's doses. The purpose of Part B is to study how much of the study drug, in capsule or tablet form, gets into the bloodstream and how long the body takes to get rid of it. In addition, the effect of food and a proton pump inhibitor (PPI) on LY2940680 will be studied. Part B will involve one group of participants who will take four single doses of 100 milligrams (mg) LY2940680. There is a minimum 7 day washout period between doses. Participants may only enroll in one part. Screening is required within 28 days prior to the start of the study.
Interventions
- DRUG Lansoprazole
- DRUG LY2940680 Capsule(s) (Reference)
- DRUG LY2940680 Tablet (Test)
- DRUG Placebo Capsule(s)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2012-09 |
| Est. Completion | 2012-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01681186
The ClinicalTrials.gov registry entry for NCT01681186 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Lansoprazole is the first listed.
NCT01681186 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01681186 about?
NCT01681186 is a clinical study titled "A Study of LY2940680 in Healthy Participants". This study involves 2 parts, Part A and Part B. The purpose of Part A is to evaluate the safety and side effects of LY2940680 in healthy participants. Part A will involve two groups of participants, each taking up to two single doses of LY2940680 at different dose levels. There is a minimum 14 day w...
What is the current status of trial NCT01681186?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2012-09. Estimated completion is 2012-12.
What interventions are being tested in trial NCT01681186?
The interventions under investigation include: Lansoprazole (DRUG), LY2940680 Capsule(s) (Reference) (DRUG), LY2940680 Tablet (Test) (DRUG), Placebo Capsule(s) (DRUG).
Who is sponsoring clinical trial NCT01681186?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.